TB-500 vs Ziconotide
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
TB-500 is a synthetic peptide that copies the active region of thymosin beta-4, a natural protein that controls how cells build and move their internal skeleton. Most TB-500 products reproduce the short LKKTETQ sequence (residues 17 to 23) responsible for binding actin and driving cell migration, which is why it gets marketed for tendon, muscle, and wound repair. Here is the honest part: there are essentially no completed human trials of the TB-500 fragment itself, and almost all the human clinical data is for the full-length thymosin beta-4 molecule, which is related but not the same thing.
Also: Prialt, SNX-111
Ziconotide is a real, FDA-approved painkiller pulled from the venom of a marine cone snail. It is not an opioid, and unlike morphine, people do not build tolerance to it over time. The catch: it only works delivered directly into the spinal fluid through an implanted pump, and its side effect profile is rough enough that it carries a black box warning.
Key Comparison Insights
- Ziconotide is FDA approved, while TB-500 remains in research stages.
- Both peptides belong to the Healing category, suggesting similar primary applications.
- Ziconotide has stronger research evidence (FDA Approved) compared to TB-500 (Animal Studies).
Detailed Comparison
| Attribute | TB-500 | Ziconotide |
|---|---|---|
| Category | Healing | Healing |
| FDA Status | Not FDA Approved | FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Thymosin beta-4 works by grabbing onto G-actin, the building-block form of actin, and acting as the main reservoir cells use to remodel their cytoskeleton. That control over actin lets cells migrate into wounds, which is the proposed basis for faster tissue repair. The active heptapeptide sequence LKKTETQ is the piece that does the actin binding, and TB-500 is built around it. Beyond cell movement, thymosin beta-4 has shown anti-inflammatory effects and pro-angiogenic activity in lab models. Keep in mind that injecting a short synthetic fragment is not guaranteed to reproduce everything the full protein does, so the mechanism story is borrowed largely from research on the parent molecule. | Ziconotide is a synthetic copy of omega-conotoxin MVIIA (originally SNX-111), a 25-amino-acid peptide with three disulfide bonds found in the venom of the cone snail Conus magus. It blocks N-type voltage-gated calcium channels, which sit on pain-sensing nerves in the spinal cord's dorsal horn. By shutting those channels, it stops the release of pain-signaling neurotransmitters before the message can travel up to the brain. It barely crosses the blood-brain barrier, which is exactly why it has to be infused intrathecally, straight into the cerebrospinal fluid, to reach its targets. |
| Common Dosing | 2-2.5 mg twice weekly (loading), then 2.5 mg once weekly (maintenance) 2x weekly for 4-6 weeks, then 1x weekly | Limited community data available See research protocols |
| Administration | Subcutaneous or intramuscular injection | Intrathecal infusion only |
| Typical Duration | 4-6 weeks loading, then maintenance | Chronic use via intrathecal pump |
| Best Time to Take | Morning or evening | Morning or as directed |
Possible Side Effects May vary by individual |
|
|
| Research Summary | The strongest evidence is preclinical and is mostly about full-length thymosin beta-4, not the TB-500 fragment. Animal studies consistently show accelerated wound healing, reduced scarring, and improved recovery in tendon, skin, and cardiac injury models. On the human side, the biotech company RegeneRx ran the molecule (as RGN-259 eye drops and RGN-352 injection) through actual clinical trials: a placebo-controlled Phase 3 study of RGN-259 in neurotrophic keratopathy reported corneal healing in 6 of 10 treated patients versus 1 of 8 on placebo, and an injectable cardiac program reached Phase 2 before a manufacturing hold. But those programs used full-length thymosin beta-4, not the 7-amino-acid TB-500 fragment sold for research. For the fragment specifically, there are no completed, published human efficacy trials for muscle or tendon repair, and a recently listed cardiovascular biomarker study is early-stage. So: real animal data, real human data for the parent protein, and a near-total gap for TB-500 as sold. | This one is the opposite of speculative. The FDA approved ziconotide as Prialt on December 28, 2004, and the European Commission followed on February 22, 2005. It is indicated for severe chronic pain in patients who need intrathecal therapy and who cannot tolerate or no longer respond to other options, including intrathecal morphine. Its big advantage over opioids is the apparent absence of tolerance or physical dependence even with long-term use. The big problem is a narrow therapeutic window: dizziness, confusion, memory problems, unsteady gait, and serious psychiatric effects including hallucinations and suicidal thoughts, which is why it carries a black box warning and is contraindicated in people with a history of psychosis. Rapid dosing or aggressive dose escalation makes the adverse effects worse, so it is titrated slowly under specialist care. |
Frequently Asked Questions: TB-500 vs Ziconotide
What is the difference between TB-500 and Ziconotide?
TB-500 is a healing peptide that tb-500 is a synthetic peptide that copies the active region of thymosin beta-4, a natural protein that controls how cells build and move their internal skeleton. most tb-500 products reproduce the short lkktetq sequence (residues 17 to 23) responsible for binding actin and driving cell migration, which is why it gets marketed for tendon, muscle, and wound repair. here is the honest part: there are essentially no completed human trials of the tb-500 fragment itself, and almost all the human clinical data is for the full-length thymosin beta-4 molecule, which is related but not the same thing. Ziconotide is a healing peptide that ziconotide is a real, fda-approved painkiller pulled from the venom of a marine cone snail. it is not an opioid, and unlike morphine, people do not build tolerance to it over time. the catch: it only works delivered directly into the spinal fluid through an implanted pump, and its side effect profile is rough enough that it carries a black box warning. The main differences lie in their mechanisms of action and clinical applications.
Which is better, TB-500 or Ziconotide?
Neither is universally "better" - the choice depends on your specific goals. TB-500 is typically used for healing purposes, while Ziconotide is used for healing. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can TB-500 and Ziconotide be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using TB-500 and Ziconotide together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.